B lymphocytes are the mediators of humoral immunity, responsible for producing antibodies that neutralize toxins, opsonize pathogens, activate complement, and prevent microbial attachment to host cells. The development of B cells from hematopoietic precursors and their subsequent activation to produce high-affinity antibodies involves sequential genetic recombination events and elegant selection mechanisms.
B Cell Development in the Bone Marrow
B cell development begins in the bone marrow from common lymphoid progenitors and proceeds through distinct stages defined by the rearrangement status of immunoglobulin genes. In the pro-B cell stage, D-J rearrangement occurs at the heavy chain locus, followed by V-DJ rearrangement in pre-B cells. Successful heavy chain rearrangement allows expression of the pre-B cell receptor (pre-BCR), consisting of the μ heavy chain paired with surrogate light chains (VpreB and λ5), which signals to promote proliferation and light chain rearrangement. The pre-BCR checkpoint tests for functional heavy chain production: cells with a functional pre-BCR receive survival and proliferation signals, while cells with non-functional rearrangements undergo apoptosis. Light chain genes (κ or λ) rearrange in small pre-B cells, and successful light chain production yields an immature B cell expressing complete IgM on its surface.
B Cell Tolerance Mechanisms
Immature B cells that recognize self-antigens with high affinity in the bone marrow are eliminated by clonal deletion (apoptosis) to establish central tolerance. B cells with moderate self-reactivity undergo receptor editing, reactivating RAG1/RAG2 to rearrange additional light chain genes and alter their specificity, with a second chance to generate a non-self-reactive receptor. B cells that recognize self-antigens with low affinity are not deleted but become anergic, functionally unresponsive to antigen stimulation. Peripheral tolerance mechanisms further regulate self-reactive B cells that escape the bone marrow, including the absence of T cell help for self-reactive B cells that require T cell-dependent activation.
B Cell Activation in Peripheral Lymphoid Organs
Mature naive B cells expressing both IgM and IgD circulate through the blood and lymph to secondary lymphoid organs. B cell activation occurs in two contexts. T cell-independent antigens, typically multivalent polysaccharides with repetitive epitopes, can activate B cells by extensive BCR cross-linking without T cell help, producing short-lived plasma cells secreting low-affinity IgM. T cell-dependent antigens, which include most protein antigens, require B cells to internalize antigen via BCR, process it, and present peptide-MHC class II complexes to antigen-specific CD4+ follicular helper T cells. The T cell provides CD40L (CD154) engagement of CD40 on the B cell and cytokines that drive B cell proliferation, class switching, and differentiation.
The Germinal Center Reaction
Activated B cells migrate into B cell follicles and proliferate rapidly to form germinal centers, specialized microenvironments within secondary lymphoid organs. Germinal centers are divided into a dark zone, where B cells undergo rapid proliferation and somatic hypermutation of their immunoglobulin variable region genes, and a light zone, where B cells with mutated BCRs compete for limited antigen retained on follicular dendritic cells and for T cell help. Somatic hypermutation is mediated by activation-induced deaminase (AID), which deaminates cytosine to uracil in immunoglobulin genes, leading to mutations at a rate of approximately 10⁻³ per base pair per generation — a million-fold higher than the background mutation rate. B cells with improved antigen-binding affinity (due to favorable mutations) receive survival signals, while those with reduced affinity undergo apoptosis, a process called affinity maturation that progressively increases antibody affinity over the course of an immune response.
Class Switch Recombination
Class switch recombination changes the antibody isotype from IgM to IgG, IgA, or IgE without altering antigen specificity, by recombining the expressed V(D)J exon with a downstream constant region gene and deleting the intervening DNA. AID initiates switch recombination by deaminating cytosines in switch regions upstream of each constant region gene. The specific cytokine milieu determines which isotype is produced: IFN-γ promotes switching to IgG subclasses (especially IgG2a in mice), IL-4 promotes switching to IgE and IgG1, and TGF-β promotes switching to IgA. Each isotype has distinct effector functions: IgG opsonizes and activates complement, IgA provides mucosal immunity, IgE triggers mast cell degranulation, and IgM is the early response antibody.
Plasma Cells and Memory B Cells
B cells that complete the germinal center reaction differentiate into either plasma cells or memory B cells. Plasma cells are terminally differentiated antibody-secreting cells with extensive endoplasmic reticulum, producing thousands of antibodies per second. Short-lived plasma cells reside in lymphoid organs for days and provide the initial wave of antibody, while long-lived plasma cells migrate to the bone marrow and continue secreting antibodies for years or decades, maintaining serum antibody levels. Memory B cells are long-lived, quiescent cells that express high-affinity BCRs, with class-switched isotypes and somatic mutations, and rapidly differentiate into plasma cells upon re-exposure to antigen, generating a faster and more robust secondary response compared to the primary response.
Monoclonal Antibodies
Monoclonal antibodies are identical antibodies produced by a single B cell clone, generated in the laboratory by fusing an antibody-producing B cell with a myeloma cell to create a hybridoma that can be cultured indefinitely. Chimeric, humanized, and fully human monoclonal antibodies have been developed to minimize immunogenicity for therapeutic use. Monoclonal antibodies are widely used clinically, including rituximab (anti-CD20) for B cell lymphomas and autoimmune diseases, trastuzumab (anti-HER2) for breast cancer, adalimumab (anti-TNF) for rheumatoid arthritis, and palivizumab (anti-RSV) for prevention of respiratory syncytial virus infection in high-risk infants.
